NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock observed trading -80.53% off 52-week high price. On the other end, the stock has been noted 0.17% away from low price over the last 52-weeks. The stock disclosed a move of -19.43% away from 50 day moving average and -46.43% away from 200 day moving average. Moving closer, we can see that shares have been trading -8.73% off 20-day moving average. It has market cap of $93.50M.
On Sept. 2, 2020, NeuroBo Pharmaceuticals (NASDAQ:NRBO) a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, released that Douglas J. Swirsky, President and Chief Executive Officer of publicly traded Rexahn Pharmaceuticals, has been appointed to the Company’s Board of Directors, effective September 1, 2020. In addition to his position as an independent director, Mr. Swirsky will also serve as a member of the Audit Committee. He replaces Steven Gullans, Ph.D., who resigned from the Board of Directors effective August 31, 2020.
Doug brings to Neurobo more than two decades of relevant experience in the biopharmaceutical and healthcare sectors, having served as a director of, or in senior management positions at, a number of publicly held companies over the last 14 years and having provided counsel to corporate clients as a healthcare investment banker, stated Richard J. Kang, Ph.D., President and Chief Executive Officer of NeuroBo. Doug’s vast industry expertise and proven leadership capabilities make him a valuable asset, and we look forward to working together on our clinical and preclinical pipeline activities. As we welcome Doug to the NeuroBo team, I want to also extend our sincere gratitude to Dr. Gullans for his service on the Board and his contributions to our merger with Gemphire.
The USA based company NeuroBo Pharmaceuticals moved with change of -3.31% to $5.84 with the total traded volume of 22767 shares in recent session versus to an average volume of 71.54K shares. The stock was observed in the 5 days activity at -7.15%. The one month performance of stock was -13.61%. NRBO’s shares are at -58.58% for the quarter and driving a -55.91% return over the course of the past year and is now at -33.26% since this point in 2018. Right now the stock beta is 0.65. The average volatility for the week and month was at 5.43% and 6.16% respectively. There are 16.30M shares outstanding and 15.74M shares are floated in market.